NasdaqCM:CAPRBiotechs
Capricor Therapeutics (CAPR): Assessing Valuation After a Strong Multi-Week Share Price Rally
Capricor Therapeutics (CAPR) has quietly rewarded patient investors, with the stock climbing sharply over the past year as expectations build around its late stage Duchenne muscular dystrophy program and broader exosome pipeline.
See our latest analysis for Capricor Therapeutics.
The recent surge, including a powerful 7 day share price return and strong gains over the past quarter, suggests momentum is firmly building as investors reprice Capricor’s late stage pipeline and long term...